(Q47795423)

5 February 2018

title

Post-marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years. (English)

1 reference

5 February 2018

1 reference

7

G Passalacqua

1 reference

5 February 2018

V Di Rienzo

1

1 reference

5 February 2018

M Minelli

2

1 reference

5 February 2018

A Musarra

3

1 reference

5 February 2018

R Sambugaro

4

1 reference

5 February 2018

S Pecora

5

1 reference

5 February 2018

W G Canonica

6

1 reference

5 February 2018

publication date

1 May 2005

1 reference

5 February 2018

Clinical & Experimental Allergy

published in

1 reference

5 February 2018

volume

35

1 reference

5 February 2018

issue

5

1 reference

5 February 2018

page(s)

560-564

1 reference

5 February 2018

Allergic rhinitis and its impact on asthma

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2005.02219.X

Noninjection routes for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2005.02219.X

Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2005.02219.X

Safety of sublingual-swallow immunotherapy in children and adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2005.02219.X

Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2005.02219.X

Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2005.02219.X

Randomized controlled open study of sublingual immunotherapy for respiratory allergy in real-life: clinical efficacy and more

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2005.02219.X

Safety of sublingual immunotherapy with a monomeric allergoid in very young children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2005.02219.X

Impact of sublingual immunotherapy on seasonal asthma and skin reactivity in children allergic to Parietaria pollen treated with inhaled fluticasone propionate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2005.02219.X

Sublingual immunotherapy: a double-blind, placebo-controlled trial with Parietaria judaica extract standardized in mass units in patients with rhinoconjunctivitis, asthma, or both.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2005.02219.X

Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2005.02219.X

10.1111/J.1365-2222.2005.02219.X

21 January 2018

Identifiers

DOI

1 reference

5 February 2018

PubMed ID

15898975

1 reference

5 February 2018